YAP1 and pulmonary arterial hypertension: Conversely, in cells pre-treated with the dual ETAR/ETBR antagonist macitentan, a FDA approved drug for the treatment of pulmonary arterial hypertension [27, 28], ET-1-induced ZEB1 and YAP/TAZ nuclear accumulation was inhibited (Fig. 1C, Additional file 3: Fig. S1A, B).